BRIEF-AstraZeneca Says Tezepelumab Granted FDA Priority Review For Asthma
- Country:
- United States
AstraZeneca PLC: * ASTRAZENECA PLC - TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA
* ASTRAZENECA - TEZEPELUMAB REGULATORY SUBMISSION ACCEPTED AND GRANTED FDA PRIORITY REVIEW IN US FOR TREATMENT OF PATIENTS WITH ASTHMA * ASTRAZENECA - PRESCRIPTION DRUG USER FEE ACT DATE, FDA ACTION DATE FOR THEIR REGULATORY DECISION, IS DURING Q1 OF 2022. Source text for Eikon: Further company coverage:
Google News